TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28992884
Drug: Intravenous moxifloxacin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous moxifloxacin (400 mg/day)
Study: 28992884
Drug: Ceftriaxone (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone (2 g/day)
Study: 26357467
Drug: LC350189 (10-600
Approvals — FDA: no, EMA: no, PMDA: no
Description: LC350189 (10-600 mg single ascending dose)
Study: 26357467
Drug: LC350189 (100-800
Approvals — FDA: no, EMA: no, PMDA: no
Description: LC350189 (100-800 mg multiple ascending dose for 7 days)
Study: 26357467
Drug: LC350189 (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: LC350189 (200 mg)
Study: 23851699
Drug: Vitamin D-fortified
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D-fortified growing up milk (2.85 μg/100 ml)
Study: 19224790
Drug: Target-controlled infusion
Normalized name: Diphtheria toxin-il-3 fusion protein targeting IL-3 receptor
DrugBank: Tagraxofusp (DB14731)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Target-controlled infusion (TCI) remifentanil (1 ng/mL)
Study: 19224790
Drug: Manually controlled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manually controlled continuous infusion (MCI) remifentanil (0.125 microg x kg(‐1) x min(‐1) for 2 min followed by 0.05 microg x kg(‐1) x min(‐1))
Study: 19224790
Drug: Placebo (normal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (normal saline either as TCI or manual infusion of equivalent rate)
Study: 11079647
Drug: Abciximab with
Normalized name: Abciximab
DrugBank: Abciximab (DB00054)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Abciximab with reduced-dose reteplase (5 U double bolus)
Study: 9387746
Drug: Antithyroid drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antithyroid drugs (Tapazol and inderal, etc.)
Study: 9387746
Drug: Chinese herbal
Normalized name: GINGER 28 mg in 100 mL TOPICAL OIL [Pain Relief Honzo Seika Chinese Herbal Aroma Oil]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chinese herbal medicine for tonifying Kidney and promoting blood circulation
Study: 1549034
Drug: Diphenhydramine hydrochloride
Normalized name: Diphenhydramine Hydrochloride
DrugBank: Diphenhydramine (DB01075)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Diphenhydramine hydrochloride (50 mg)
Study: 381093
Drug: Cimetidine (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine (300 mg four times daily)
Study: 26866405
Drug: 2-stage injection
Normalized name: SAGE
DrugBank: Sage (DB10982)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-stage injection technique
Study: 20383871
Drug: EPO treatment
Normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: EPO treatment at a fixed dose of 50 IU/kg per week to increase hemoglobin level to a maximum of 13.7 g/dL for men and 13.4 g/dL for women.
Study: 20383871
Drug: EPO treatment
Normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: EPO treatment at a fixed dose of 50 IU/kg per week maintaining baseline hemoglobin levels for the first 6 months by phlebotomy.
Study: 16293867
Drug: Standard chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard chemotherapy (cyclophosphamide, doxorubicin, etoposide; cisplatin and etoposide)
Study: 16293867
Drug: ICE-V regimen
Normalized name: Anacin Aspirin Regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICE-V regimen and Standard chemotherapy
Study: 12564654
Drug: Formoterol fumarate
Normalized name: Formoterol Fumarate
DrugBank: Formoterol (DB00983)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Formoterol fumarate (Foradil) 12 microg taken twice daily
Study: 12564654
Drug: Formoterol fumarate
Normalized name: Formoterol Fumarate
DrugBank: Formoterol (DB00983)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Formoterol fumarate (Foradil) 24 microg taken twice daily
Study: 12564654
Drug: Formoterol fumarate
Normalized name: Formoterol Fumarate
DrugBank: Formoterol (DB00983)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Formoterol fumarate (Foradil) used as regular maintenance treatment and rescue medication
Study: 12564654
Drug: Formoterol fumarate
Normalized name: Formoterol Fumarate
DrugBank: Formoterol (DB00983)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Formoterol fumarate (Foradil) total daily dose of 48 microg or less
Study: 10214889
Drug: Azelastine hydrochloride
Normalized name: Azelastine Hydrochloride
DrugBank: Azelastine (DB00972)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Azelastine hydrochloride (AZ) 2 mg + S-carboxymethyl cysteine (SCMC) 750 mg
Study: 10214889
Drug: S-carboxymethyl cysteine
Normalized name: (R)-S-(carboxymethyl)cysteine
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-carboxymethyl cysteine (SCMC) 750 mg
Study: 7611378
Drug: 1 mg/day
Normalized name: Lyllana 0.1 MG/Day Transdermal Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg/day digoxin
Study: 30702997
Drug: Dual pathway
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual pathway inhibition with low-dose rivaroxaban (2.5 mg twice-daily) plus acetylsalicylic acid
Study: 26717035
Drug: Conventional tacrolimus-based
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conventional tacrolimus-based therapy (TAC Control)
Study: 21870979
Drug: Omega-3 fatty
Normalized name: Omega-3 fatty acid
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omega-3 fatty acids (1 g twice a day)
Study: 10065662
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg patch for 22 weeks (L-25)
Study: 10065662
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg patch for 8 weeks (S-25)
Study: 10065662
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg patch for 22 weeks (L-15)
Study: 10065662
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg patch for 8 weeks (S-15)
Study: 7488408
Drug: Postoperative platinum-based
Normalized name: platinum
DrugBank: Platinum (DB12257)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative platinum-based chemotherapy (two cycles)
Study: 1962154
Drug: Pulsed ultrasound
Normalized name: ULTRASOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulsed ultrasound treatment (1 MHz; 1:4; 1 W/cm2, 10 min/session, 2-3 times weekly for 10 treatments)
Study: 26071040
Drug: TXA 1
Normalized name: Tranexamic acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: TXA 1 g
Study: 23873583
Drug: Double therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double therapy (peginterferon α‐2b and ribavirin for 20 weeks)
Study: 23873583
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy (peginterferon α‐2b, ribavirin, and boceprevir for 24 weeks)
Study: 22313979
Drug: Adper Prompt‐L‐Pop
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adper Prompt‐L‐Pop
Study: 20571786
Drug: teriparatide treatment
Normalized name: Teriparatide
DrugBank: Teriparatide (DB06285)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: teriparatide treatment (20 microg/day)
Study: 2261895
Drug: Full cream
Normalized name: Full Marks
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full cream cows' milk or low lactose formula
Study: 6805002
Drug: Pimozide (10-70
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pimozide (10-70 mg/day, median 30 mg/day)
Study: 6805002
Drug: Chlorpromazine (600-1500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorpromazine (600-1500 mg/day, median 900 mg/day)
Study: 28727908
Drug: MK-8666 500
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-8666 500 mg
Study: 28727908
Drug: MK-8666 150
Normalized name: MK-8666
DrugBank: MK-8666 (DB14937)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-8666 150 mg
Study: 28727908
Drug: MK-8666 50
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-8666 50 mg
Study: 26348088
Drug: Sertraline (SRT)
DrugBank: Sertraline (DB01104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sertraline (SRT) treatment, maximum dose 200 mg/day, over 72-300 days (mean=164.2, SD=68.3).
Study: 23566419
Drug: Celecoxib (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celecoxib (400 mg) twice daily for two to three weeks (n = 22)
Study: 19549430
Drug: Mometasone 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mometasone 400 micrograms once daily for 12 weeks
Study: 15143476
Drug: 11PncTD1 (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 11PncTD1 (1 dose of adjuvanted, 11-valent pneumococcal conjugate vaccine)
Study: 15143476
Drug: 11PncTD3 (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: 11PncTD3 (3 doses of adjuvanted, 11-valent pneumococcal conjugate vaccine)
Study: 8729585
Drug: Fluvastatin 20
Normalized name: fluvastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvastatin 20 mg and 40 mg
Study: 1568660
Drug: Ursodeoxycholic acid
Normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ursodeoxycholic acid (UDCA, 12 mg/kg/day)
Study: 1568660
Drug: Chenodeoxycholic acid
Normalized name: Chenodeoxycholic acid
DrugBank: Chenodeoxycholic acid (DB06777)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chenodeoxycholic acid (CDCA, 12 mg/kg/day)
Study: 1568660
Drug: Bedtime administration
Normalized name: Buckley's Bedtime Formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bedtime administration of UDCA
Study: 1568660
Drug: Mealtime administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mealtime administration of UDCA
Study: 1568660
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (CDCA 6 mg/kg/day + UDCA 6 mg/kg/day at bedtime)
Study: 30526264
Drug: Scopolamine patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scopolamine patch
Study: 24706493
Drug: Fesoterodine 4
Normalized name: fesoterodine 4 mg oral tablet, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fesoterodine 4 to 8 mg
Study: 22120090
Drug: Tolvaptan 15-120
Normalized name: tolvaptan 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolvaptan 15-120 mg single dose
Study: 22120090
Drug: Tolvaptan 30-120
Normalized name: tolvaptan 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolvaptan 30-120 mg once daily for 7 days
Study: 22120090
Drug: Tolvaptan 60
Normalized name: tolvaptan 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolvaptan 60 mg and above
Study: 18219850
Drug: Trastuzumab alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trastuzumab alone therapy (A-group)
Study: 18219850
Drug: Trastuzumab plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trastuzumab plus taxane therapy (B-group)
Study: 18219850
Drug: Trastuzumab plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trastuzumab plus taxane therapy (after addition to A-group)
Study: 3605748
Drug: Thiopental treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiopental treatment (EEG suppression)
Study: 3605748
Drug: Isoflurane treatment
Normalized name: Isoflurane
DrugBank: Isoflurane (DB00753)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isoflurane treatment (EEG suppression)
Study: 28672405
Drug: Long-term antidepressant
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term antidepressant treatment (SSRI/SNRI) for 6-52 weeks
Study: 28672405
Drug: No antidepressant
Approvals — FDA: no, EMA: no, PMDA: no
Description: No antidepressant treatment (with or without benzodiazepine medication)
Study: 25537835
Drug: Diluted insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Diluted insulin aspart (20 U/ml)
Study: 25537835
Drug: Standard insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard insulin aspart (100 U/ml)
Study: 22084206
Drug: Standard CTPA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard CTPA (100-120 kVp) with standard contrast medium injection (n = 46)
Study: 20815182
Drug: Recovery sleep
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recovery sleep doses of 0, 2, 4, 6, 8, or 10 h TIB after 5 nights of sleep restriction to 4 h TIB
Study: 19083445
Drug: BTE tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: BTE tablets (333 mg)
Study: 12785023
Drug: High-dose sclerotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose sclerotherapy (Group B)
Study: 10716475
Drug: Candesartan cilexetil
Normalized name: Candesartan Cilexetil
DrugBank: Candesartan cilexetil (DB00796)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Candesartan cilexetil (Ang II type 1 receptor antagonist)
Study: 29525929
Drug: Perceived need
Normalized name: diphenhydramine
DrugBank: Diphenhydramine (DB01075)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Perceived need for treatment
Study: 24514907
Drug: High-intensity exercise
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-intensity exercise training with 250 mg resveratrol
Study: 24514907
Drug: Resveratrol (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resveratrol (250 mg)
Study: 22395588
Drug: 5% dexpanthenol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% dexpanthenol (DT) ointment
Study: 22395588
Drug: 1% hydrocortisone
Normalized name: HYDROCORTISONE 0.01 g in 1 g TOPICAL OINTMENT [AFASSCO 1% Hydrocortisone]
DrugBank: Hydrocortisone (DB00741)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 1% hydrocortisone (HC) ointment
Study: 20808314
Drug: Siltuximab 3
Normalized name: Siltuximab
DrugBank: Siltuximab (DB09036)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Siltuximab 3 mg/kg, q3w × 4
Study: 20808314
Drug: Siltuximab 6
Normalized name: Siltuximab
DrugBank: Siltuximab (DB09036)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Siltuximab 6 mg/kg, q3w × 4
Study: 20808314
Drug: Siltuximab 6
Normalized name: Siltuximab
DrugBank: Siltuximab (DB09036)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Siltuximab 6 mg/kg, q2w × 6
Study: 19025059
Drug: Estalin 2
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Estalin 2 mg tablets (test formulation)
Study: 19025059
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg tablets of the originator product (reference formulation)
Study: 15998754
Drug: Combination antiretroviral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination antiretroviral regimens, elective cesarean section in selected patients, avoidance of breastfeeding
Study: 12841803
Drug: Exposure to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exposure to direct-to-consumer advertisements for osteoporosis drugs
Study: 11815322
Drug: Zinc supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc supplementation (10 mg elemental Zn/d in cherry syrup)
Study: 11815322
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (cherry syrup alone)
Study: 8775955
Drug: Direct referral
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Direct referral to oral and maxillofacial surgery
Study: 2139283
Drug: 40 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 micrograms dose, 4 dose vaccination schedule
Study: 2139283
Drug: 40 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 micrograms dose, 3 dose vaccination schedule
Study: 2139283
Drug: 40 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 micrograms dose, 0, 1, 2, 6 month schedule
Study: 2139283
Drug: 40 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 micrograms dose, 0, 1, 2, 12 month schedule
Study: 2139283
Drug: 20 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 micrograms dose
Study: 7018854
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg Ro 13-9904
Study: 7018854
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg Ro 13-9904
Study: 7018854
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg tobramycin
Study: 6368877
Drug: Acyclovir (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acyclovir (200 mg) five times daily for five days
Study: 24906976
Drug: Metformin (M)
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Metformin (M) 2 g/day
Study: 24906976
Drug: Metformin (M)
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Metformin (M) 2 g/day + Oral contraceptive pills (OCP) (150 mg desogestrel + 30 microgram ethinylestradiol)
Study: 10905421
Drug: Abuse-focused cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abuse-focused cognitive behavioral therapy
Study: 2408515
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg t.i.d. tritoqualine for three days
Study: 2408515
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg t.i.d. tritoqualine for three days (in patients with a history of allergy)
Study: 25641662
Drug: Sunitinib (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sunitinib (50 mg daily in 6-week cycles: 4 weeks on treatment, 2 weeks off treatment)
Study: 27094801
Drug: Pregabalin with
Normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pregabalin with sham treatment
Study: 12859466
Drug: Saline 1
Normalized name: normal saline 10 mL Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline 1 ml.kg‐1 (group S)
Study: 6209900
Drug: Meclosorb cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meclosorb cream
Study: 6209900
Drug: Tetracycline tablets
Normalized name: Oxytetracycline Tablets
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tetracycline tablets (500 mg daily)
Study: 21401662
Drug: Functional Electrical
Normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Functional Electrical Stimulation (FES) therapy
Study: 14666739
Drug: Oral-B CrossAction
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral-B CrossAction Power
Study: 8839728
Drug: Oral exhaled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral exhaled NO in asthmatic children
Study: 8839728
Drug: Oral exhaled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral exhaled NO in healthy controls
Study: 8839728
Drug: Correlation between
Approvals — FDA: no, EMA: no, PMDA: no
Description: Correlation between oral exhaled NO and FeV1
Study: 8839728
Drug: Correlation between
Approvals — FDA: no, EMA: no, PMDA: no
Description: Correlation between oral/nasal exhaled NO and other markers
Study: 22157100
Drug: Intra-articular dexamethasone
Normalized name: dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intra-articular dexamethasone administration after arthrocentesis
Study: 22157100
Drug: Saline (placebo)
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline (placebo) administration after arthrocentesis
Study: 19751247
Drug: Prucalopride 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prucalopride 0.5 mg once daily for 28 days
Study: 19751247
Drug: Prucalopride 1
Normalized name: prucalopride 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prucalopride 1 mg once daily for 28 days
Study: 19751247
Drug: Prucalopride 2
Normalized name: prucalopride 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prucalopride 2 mg once daily for 28 days
Study: 2124179
Drug: Levonorgestrel 20
Normalized name: ethinyl estradiol-levonorgestrel 20 mcg-90 mcg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levonorgestrel 20 mcg/day (LNg 20)
Study: 400246
Drug: Therapist-conducted, face-to-face
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapist-conducted, face-to-face progressive, deep-muscle relaxation training for 10 weekly sessions
Study: 400246
Drug: Progressive deep-muscle
Normalized name: Deep Sea
Approvals — FDA: no, EMA: no, PMDA: no
Description: Progressive deep-muscle relaxation therapy conducted mainly by home use of audio cassettes
Study: 400246
Drug: Nonspecific individual
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nonspecific individual psychotherapy for 10 weekly sessions
Study: 26158794
Drug: Co-administration of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co-administration of tofogliflozin and anti-T2DM drugs
Study: 26158794
Drug: Anti-T2DM drugs
Normalized name: anti-CD11a
DrugBank: Efalizumab (DB00095)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Anti-T2DM drugs alone
Study: 19539103
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of 30 mg duloxetine
Study: 19539103
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of 60 mg duloxetine
Study: 19539103
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of 90 mg duloxetine
Study: 19539103
Drug: Multiple doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple doses of 30 mg duloxetine (twice daily for 7 days)
Study: 15261565
Drug: Methylprednisolone (MP)
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylprednisolone (MP) once monthly for 6 months
Study: 3896288
Drug: First line
Normalized name: ALCOHOL 0.75 mL in 1 mL TOPICAL CLOTH [First Line Alcohol Wipes]
Approvals — FDA: no, EMA: no, PMDA: no
Description: First line therapy (Melphalan and Prednisone)
Study: 3896288
Drug: Continuation of
Normalized name: varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuation of first line therapy for a further year
Study: 29215971
Drug: Mediterranean-style diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mediterranean-style diet (MedDiet) supplemented with fish oil, received fortnightly food hampers and MedDiet cooking workshops for 3 months and fish oil supplements for 6 months
Study: 22173041
Drug: Daily mild
Normalized name: Octinoxate 3.50 g in 50 mL / Homosalate 3.00 g in 50 mL / Octisalate 2.25 g in 50 mL TOPICAL CREAM [VILLAGE11FACTORY DAILY MILD SUN]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily mild home exercises (calisthenics focusing on balance-control, low-back-connected musculature) for 15 minutes daily over 2 months
Study: 20202636
Drug: 1000 mg
Normalized name: bran 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg Mycophenolate mofetil (MMF) BD for at least 2 weeks
Study: 12232562
Drug: Venoruton (HR)
DrugBank: Oxerutins (DB15826)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venoruton (HR) 2 g/day for 8 weeks
Study: 12232562
Drug: Daflon (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daflon (500 mg) three tablets daily every 8 hours